Icosavax Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares SEATTLE, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...

CureVac Announces U.S. Patent Grant for mRNA Vaccination of Infants Against RSV Important New Patent to Allow CureVac to Develop Vaccine Candidate for Neglected Respiratory Condition TÜBINGEN, Germany and BOSTON, Jan. 08, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully...

Infectious Diseases a Hot Topic at the International Society for Heart and Lung Transplantation 38th Annual Meeting and Scientific Sessions NICE, FR, April 13, 2018 (GLOBE NEWSWIRE) -- During Oral Session 38 at the International Society for Heart and Lung Transplantation (ISHLT) 38th Annual Meeting & Scientific Sessions, two studies...